… s efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate the
efficacy of anlotinib … trial designed to evaluate the efficacy and safety of anlotinib in patients with …

… Anlotinib is a multitarget tyrosine kinase inhibitor, mainly targets VEGFR1-3. This phase III
trial was conducted to evaluate anti-tumor efficacy and safety of anlotinib … into anlotinib or …

… Maintenance treatment was followed by using pemetrexed and anlotinib (anlotinib alone for
… of anlotinib and chemotherapy showed the potential effect and a manageable safety profile …

… Anlotinib is an oral novel multitargeted TKI that inhibits angiogenesis and … efficacy and
safety of EFGR T90M-positive NSCLC patients who received osimertinib combined with anlotinib …

… In conclusion, Anlotinib holds promise in treating patients with advanced gynecological
cancer including its disease-specific types, with reasonable efficacy and tolerable safety. …

… efficacy and safety of anlotinib in … efficacy and safety of anlotinib in patients with SCLC and
pleural effusion. The results showed that the ORR, DCR, and PFS were higher in the anlotinib …

… The primary goal of this study was to evaluate the efficacy and safety of anlotinib plus XELOX
in patients with mCRC. The study was performed in accordance with the principles of Good …

… in the anlotinib‐combination group had better recovery than those in the anlotinib‐monotherapy
group. Although the overall incidence of adverse reactions in the anlotinib‐combination …

… the efficacy and safety of sintilimab combined with anlotinib … generate more clinical evidence
on efficacy, safety, quality of life… sintilimab plus anlotinib has exhibited encouraging efficacy, …

… Anlotinib was the standard monotherapy for patients with … investigate the efficacy and safety
of anlotinib combined with … investigate the efficacy and safety of anlotinib combined with …